Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study

American Heart Journal

Volumn 155, Issue 2, 2008, Pages 303-309

  Marcus, Gregory M ^a   Whooley, Mary A ^b,d   Glidden, David V ^b   Pawlikowska, Ludmila ^a   Zaroff, Jonathan G ^c   Olgin, Jeffrey E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 38349098963     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.09.006     Document Type: Article

References (32)

1. Chugh S.S., Blackshear J.L., Shen W.K., et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37 (2001) 371-378
2. Kumagai K., Nakashima H., Urata H., et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 (2003) 2197-2204
3. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100 (1999) 87-95
4. Frustaci A., Chimenti C., Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
5. Marcus G.M., Yang Y., Varosy P.D., et al. Regional left atrial voltage in patients with atrial fibrillation. Heart Rhythm 4 (2007) 138-144
6. Chung M.K., Martin D.O., Sprecher D., et al. C-Reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
7. Ellinor P.T., Low A., Patton K.K., et al. C-Reactive protein in lone atrial fibrillation. Am J Cardiol 97 (2006) 1346-1350
8. Morrow DA, Ridker PM. C-Reactive protein, inflammation, and coronary risk. Med Clin North Am 2000;84:149-161, ix.
9. Benjamin E.J., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994) 840-844
10. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8 Suppl 2 (2006) S2
11. Conway D.S., Buggins P., Hughes E., et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43 (2004) 2075-2082
12. Conway DS, Buggins P, Hughes E, et al. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004;93:1368-1373, A1366.
13. Psychari S.N., Apostolou T.S., Sinos L., et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95 (2005) 764-767
14. Gaudino M., Andreotti F., Zamparelli R., et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?. Circulation 108 10 Suppl 1 (2003) II195-II199
15. Bittar M.N., Carey J.A., Barnard J., et al. Interleukin 6 G-174C polymorphism influences outcome following coronary revascularization surgery. Heart Surg Forum 8 (2005) E140-E145 [discussion E145]
16. Ruo B., Rumsfeld J.S., Hlatky M.A., et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 290 (2003) 215-221
17. Hsu T.M., and Kwok P.Y. Homogeneous primer extension assay with fluorescence polarization detection. Methods Mol Biol 212 (2003) 177-187
18. Zaroff J.G., Pawlikowska L., Miss J.C., et al. Adrenoceptor polymorphisms and the risk of cardiac injury and dysfunction after subarachnoid hemorrhage. Stroke 37 (2006) 1680-1685
19. Conway D.S., Buggins P., Hughes E., et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 148 (2004) 462-466
20. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38 (2001) 1231-1266
21. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 41 3 Pt 2 (2003) 834-841
22. Goser S., Ottl R., Brodner A., et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112 (2005) 3400-3407
23. McDermott D.H., Yang Q., Kathiresan S., et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112 (2005) 1113-1120
24. Calabrese F., Carturan E., Chimenti C., et al. Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol 17 (2004) 1108-1118
25. Satoh M., Nakamura M., Satoh H., et al. Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol 36 (2000) 1288-1294
26. Tuomisto K., Jousilahti P., Sundvall J., et al. C-Reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemos 95 (2006) 511-518
27. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
28. Roldan V., Marin F., Blann A.D., et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 24 (2003) 1373-1380
29. Luckett L.R., and Gallucci R.M. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. Br J Dermatol 156 (2007) 1163-1171
30. Xu J., Cui G., Esmailian F., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363-368
31. Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Inves 102 (1998) 1369-1376
32. Terry C.F., Loukaci V., and Green F.R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275 (2000) 18138-18144